N1,6-dimethylbenzene-1,2-diamine | 73902-65-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N1,6-dimethylbenzene-1,2-diamine
• 英文别名: 3,N2-dimethyl-benzene-1,2-diamine；2-N,3-dimethylbenzene-1,2-diamine
• CAS: 73902-65-5
• 化学式: C₈H₁₂N₂
• 分子量: 136.197
• InChiKey: LITJVIDAGYUHGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N1,6-dimethylbenzene-1,2-diamine 在 甲基二甲氧基硅烷 、 copper diacetate 、 氯化铵 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 20.0h， 生成 2-(3-cyclohexylallyl)-1,7-dimethyl-1H-benzo[d]imidazole
  参考文献：
  名称：

  Cu催化苯并咪唑与艾伦的C-H烯丙基化

  摘要：

  已经描述了 CuH 催化的苯并咪唑与丙二烯的分子内环化和分子间烯丙基化。在Cu(OAc) 2 /Xantphos的催化体系和催化量的(MeO) 2 MeSiH的作用下，反应顺利进行。该协议具有温和的反应条件和对带有吸电子、给电子或电子中性基团的底物的良好耐受性。针对该氢化铜催化体系提出了一种新的催化机理。

  DOI：

  10.1021/acs.orglett.1c02346
• 作为产物：
  描述：

  2-氯-3-硝基甲苯 在 氢气 、 铜 作用下， 以 乙醇 、 水 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 11.0h， 生成 N1,6-dimethylbenzene-1,2-diamine
  参考文献：
  名称：

  Discovery of 2-iminobenzimidazoles as potent hepatitis C virus inhibitors with a novel mechanism of action

  摘要：

  In this report we describe 2-iminobenzimidazole (IBI) analogs, identified during the course of a phenotypic high-throughput screening campaign, as novel hepatitis C virus (HCV) inhibitors. A series of IBI derivatives was synthesized and evaluated for their inhibitory activity against infectious HCV. Among the IBIs derivatives studied in this work, we identified promising compounds with high antiviral efficacy, high selectivity index and good microsomal stability. Noteworthy, the IBI series exhibited inhibitory activity on early and late steps of the viral cycle, but not in the HCV replicon system demonstrating a mechanism of action distinct from clinical-stage and approved anti-HCV drugs. Overall, our results suggest that IBIs are predestinated for further exploration as lead compounds for novel HCV interventions. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.030

文献信息

• Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
  申请人：Egle Ian

  公开号：US20090192169A1

  公开（公告）日：2009-07-30

  Compounds of Formula I: wherein A, B, D, L, R 1 , R 2 , R 3 , R 4 , m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  式I的化合物： 其中A、B、D、L、R1、R2、R3、R4、m和n的定义如描述中所定义。本发明还涉及制备这些化合物的方法，以及用于制备的新中间体，含有这些化合物的药物组合物，以及这些化合物在治疗中的应用。
• Regioselective Radical Arene Amination for the Concise Synthesis of <i>ortho</i>-Phenylenediamines
  作者：James E. Gillespie、Charlotte Morrill、Robert J. Phipps

  DOI：10.1021/jacs.1c05531

  日期：2021.6.30

  relevant diazoles. Our method can deliver both free amines and monoalkyl amines allowing access to unsymmetrical, selectively monoalkylated benzimidazoles and benzotriazoles. As well as providing concise access to valuable ortho-phenylenediamines, this work demonstrates the potential for utilizing noncovalent interactions to control positional selectivity in radical reactions.

  直接从 C-H 键形成芳烃 C-N 键非常重要，最近通过自由基机制实现这一目标的方法得到了快速发展，通常涉及反应性N中心自由基。与这些进步相关的一个主要挑战是区域控制，在大多数协议中获得了区域异构产品的混合物，限制了更广泛的应用。我们设计了一个系统，该系统利用阴离子底物和进入的自由基阳离子之间有吸引力的非共价相互作用，以将后者引导到芳烃邻位。阴离子底物采用氨基磺酸盐保护的苯胺的形式，氨基化后氨基磺酸盐基团的伸缩裂解直接导致邻位-苯二胺，一系列与药用相关的二唑的关键组成部分。我们的方法可以提供游离胺和单烷基胺，从而可以获得不对称的、选择性单烷基化的苯并咪唑和苯并三唑。除了提供对有价值的邻苯二胺的简洁访问外，这项工作还证明了利用非共价相互作用来控制自由基反应中的位置选择性的潜力。
• Linear Free Energy Substituent Effect on Flavin Redox Chemistry
  作者：Justin J. Hasford、Carmelo J. Rizzo

  DOI：10.1021/ja972992n

  日期：1998.3.1

  A systematic study on the effect of various substituents at the 7- and/or 8-position on the redox properties of isoalloxazines (flavins) is reported. The redox properties of these flavin derivative...

  系统研究了 7 位和/或 8 位的各种取代基对异恶嗪（黄素）氧化还原特性的影响。这些黄素衍生物的氧化还原特性...
• Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3
  作者：Martin E. Hayes、Grier A. Wallace、Pintipa Grongsaard、Agnieszka Bischoff、Dawn M. George、Wenyan Miao、Michael J. McPherson、Robert H. Stoffel、David W. Green、Gregory P. Roth

  DOI：10.1016/j.bmcl.2008.01.074

  日期：2008.3

  High-throughput screening identified a low molecular weight antagonist of CXCR3 displaying micromolar activity in a membrane filtration-binding assay. Systematic modi. cation of the benzimidazole core and tethered acetophenone moiety established tractable SAR of analogs with improved physicochemical properties and sub-micromolar activity across both human and murine receptors. (c) 2008 Elsevier Ltd. All rights reserved.
• 1,2,4-Triazolo[4,3-a]quinoxaline-1,4-diones as antiallergic agents
  作者：Bernard Loev、John H. Musser、Richard E. Brown、Howard Jones、Robert Kahen、Fu Chih Huang、Atul Khandwala、Paula Sonnino-Goldman、Mitchell J. Leibowitz

  DOI：10.1021/jm00381a016

  日期：1985.3

  A series of new 1,4-dihydro-1,2,4-triazolo[4,3-]quinoxaline-1,4-diones has been prepared. These compounds were tested as inhibitors of antigen-induced release of histamine (AIR) in vitro from rat peritoneal mast cells (RMC) and as inhibitors of IgE-mediated rat passive cutaneous anaphylaxis (PCA). Most of this new class of antiallergic agents showed good activity in the RMC and PCA tests. The most potent compound, 2-acetyl-7-chloro-5-n-propyl-1,2,4-triazolo[4,3-a]quinoxaline-1,4-dione (1x), with an I50 value of 0.1 microM, is 30 times more potent than disodium cromoglycate (DSCG) in the RMC assay.